However, by contrast, SEMA6D overexpression is associated with resistance to cisplatin in osteosarcoma (OS) cells, which is regulated by miR-506, demonstrating that these effects may be specific to cancer types or to chemotherapy agents. This evidence concerns the gene SEMA6D and cancer.